# US 2026/0083843 A1 · Immune cells targeting epcam and medical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083843 A1
- Document ID: US20260083843A1
- Status: Published application
- Kind: A1
- Application number: 18/869,768
- Filed: 2023-06-05
- Published: 2026-03-26
- Earliest claimed: 2022-06-10
- Assignees: Suzhou Immunohead Biotechnology Co., Ltd
- Applicants: Suzhou Immunofoco Biotechnology Co., Ltd
- Inventors: Suqiong Wang
- Web page: https://patentgrep.com/patent/US20260083843A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4254: {Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/30: from tumour cells
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/50: Colon
- A61K 2239/51: Stomach
- A61K 2239/54: Pancreas
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the technical field of biomedicine, and specifically relates to immune cells targeting EpCAM and a medical use thereof. Provided is a use of immune cells in the preparation of a drug for preventing or treating a tumor; the immune cells are cells for adoptive immune cell therapy, which can target and kill EpCAM-expressing cells; and the tumor expresses EpCAM and is a metastatic tumor.

## Claims

### Claim at position 1

-11. (canceled)

### Claim 12

A method for preventing or treating a tumor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of immune cells wherein the immune cell is a cell for an adoptive immune cell therapy, which can target and kill an EpCAM-expressing cell, and wherein the tumor expresses EpCAm and is a tumor with a metastasis.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the tumor is a gastrointestinal tumor, pancreatic cancer, ovarian cancer, or bladder cancer.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the gastrointestinal tumor is gastric cancer or colorectal cancer.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the tumor is gastric cancer with a peritoneal metastasis.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the tumor is colorectal cancer with a liver metastasis.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the immune cell is a T cell, an NK cell, or a DC cell.

### Claim 18 (depends on 12)

The method according to claim 12, wherein the cell expresses a chimeric antigen receptor having an extracellular antigen-recognition domain for recognizing an EpCAM antigen.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the antigen-recognition domain comprises a sc-Fv, preferably comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 set forth in SEQ ID NOs: 1-3, respectively, and a light chain CDR1, a light chain CDR2, and a light chain CDR3 set forth in SEQ ID NOs: 4-6, respectively.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the sc-Fv comprises a heavy chain variable region set forth in any one of SEQ ID NOs: 7-11 and a light chain variable region set forth in any one of SEQ ID NOs: 12-15.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the sc-Fv comprises a heavy chain variable region set forth in SEQ ID NO: 8 and a light chain variable region set forth in SEQ ID NO: 13.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the chimeric antigen receptor has an amino acid sequence set forth in SEQ ID NO: 16.

### Claim 23

A pharmaceutical composition for preventing or treating a tumor, comprising a therapeutically effective amount of immune cells, wherein the immune cell is a cell for an adoptive immune cell therapy, which can target and kill an EpCAM-expressing cell, and wherein the tumor expresses EpCAM and is a tumor with a metastasis.
